Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 33
---
price of $26.9999 per Class B Unit, with each Class B Unit consisting of (a) one pre-funded warrant, exercisable for one Depositary Share,
(b) one Series E Warrant, and (c) one Series F Warrant. The aggregate gross proceeds to the Company were approximately $6.0 million.
Additionally, we issued warrants to purchase 4,800 of our Depositary Shares in connection with the offering to the underwriter, or the
December 2023 Underwriter Warrants.

On February 26, 2024, in connection
with our Company’s obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceutical
Co. Ltd.

On April 29, 2024, in connection
with the closing of the transaction contemplated by the license and collaboration agreement with Rapamycin Holdings, Inc. d/b/a Emtora
Biosciences, Inc., or Emtora, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by certain warrant inducement letters, we issued an aggregate of 124,181 Depositary Shares to certain
holders of our Series E Warrants and Series F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at
an exercise price of $37.50 per share. In addition, we issued to such holders an aggregate of 94,358 Series G warrants, or the Series
G Warrants, and 147,805 Series H warrants, or the Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.05
million, before deducting agent fees and expenses. Additionally, we issued warrants to purchase 6,456 of our Depositary Shares in connection
with the offering to the warrant agent and certain of their designees, or Warrant Agent Warrants.

Between December 21, 2023
and April 1, 2025, we have issued 2,477,566,800 Ordinary Shares upon the exercise of the pre-funded warrants, Series E Warrants and Series
F Warrants issued in the December 2023 underwritten public offering and private placement, including warrants exercised pursuant to the
terms of the letter agreements entered into with certain accredited investors on May 22, 2024, or the Warrant Agreements (other than shares